Finance
UK's Indivior appoints Joe Ciaffoni as CEO
Published by Global Banking & Finance Review®
Posted on February 27, 2025
1 min readLast updated: January 25, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on February 27, 2025
1 min readLast updated: January 25, 2026
Indivior appoints Joe Ciaffoni as CEO, replacing Mark Crossley. The change comes amid a projected 17% revenue decline due to weak sales.
(Reuters) - British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.
Crossley, who joined the company in 2012, will be stepping down after a near five-year tenure as the company's CEO, Indivior said.
Ciaffoni, an independent non-executive director at the firm since December 2024, will assume the leadership role pending shareholder approval of a new remuneration policy at the annual general meeting in May, the company said in a statement.
Last week, the drugmaker projected a 17% fall in 2025 net revenue, partly due to weak sales of its film-form medication-assisted therapy.
(Reporting by Raechel Thankam Job; Editing by Mrigank Dhaniwala and Varun H K)
Joe Ciaffoni has been appointed as the new CEO of Indivior, replacing Mark Crossley.
Mark Crossley is stepping down after nearly five years as CEO, as announced by Indivior.
Joe Ciaffoni has been an independent non-executive director at Indivior since December 2024.
Indivior projected a 17% fall in net revenue for 2025, partly due to weak sales of its film-form medication-assisted therapy.
Joe Ciaffoni will assume the leadership role pending shareholder approval of a new remuneration policy at the annual general meeting.
Explore more articles in the Finance category
